Applied DNA Sciences Inc (APDN) FinancialsAPDNFinancialApplied DNA Sciences Inc

Applied DNA Sciences Inc (APDN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product and authentication services - Large scale DNA production, accounting for 33.9% of total sales, equivalent to $333.66K. Other significant revenue streams include Product and authentication services - Supply chain and Clinical laboratory testing services (over-time). Understanding this composition is critical for investors evaluating how APDN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Applied DNA Sciences Inc maintains a gross margin of 1.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1213.58%, while the net margin is -1198.42%. These profitability ratios, combined with a Return on Equity (ROE) of -685.66%, provide a clear picture of how effectively APDN converts its operational activities into shareholder value.

In the context of the broader market, APDN competes directly with industry leaders such as TCRT and SPRB. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, APDN's gross margin of 1.69% stands against TCRT's N/A and SPRB's N/A. Such benchmarking helps identify whether Applied DNA Sciences Inc is trading at a premium or discount relative to its financial performance.